Advanced or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Intrahepatic cholangiocarcinoma (iCCA) is a rare, highly aggressive, and often fatal primary epithelial cancer arising within the liver. iCCAs are diagnosed mainly at an advanced non-curable stage and usually occur sporadically in patients without recognizable risk factors. More than 90% of iCCAs are adenocarcinomas exhibiting biliary differentiation biomarkers and can be subdivided by genomic and epigenomic profiling into etiologically distinct subtypes. Unlike hepatocellular carcinoma (HCC), most iCCAs develop in the non-cirrhotic liver, although it has been reported that about 8–10% of all it occurs in patients with liver cirrhosis. Unlike conventional HCCs, mass-forming iCCAs are typically characterized by a prominent desmoplastic and hypovascularized tumor stroma, which often represents the dominant histological feature of the tumor. Curative intent surgical resection is the best option for achieving long-term survival outcomes. However, only a fraction of iCCA patients are candidates for corrective intent surgery. Moreover, the recurrence rates for iCCA after surgery are very high, from 40 to 80%, with less than one-third of the patients who undergo curative-intent surgery found to survive beyond five years after resection.

·       The incidence of Intrahepatic cholangiocarcinoma (iCCA) ranges from 0.5 to 1.04 per 100,000 population in the USA.

Thelansis’s “Advanced or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Advanced or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Advanced or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Advanced or Metastatic Intrahepatic Cholangiocarcinoma (iCCA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033